Rosie McDowell

Associate, UK and European Patent Attorney
London, EIP Europe LLP

Rosie is a life sciences specialist with experience in prosecuting patent applications in a wide range of technologies including DNA sequencing, biofuels, antibodies, microbiology, pharmaceutics, assay technologies, immunology and oil recovery.

Rosie has advised universities, multinationals and SMEs on all stages of the patent process, from patentability to grant and has gained experience in all aspects of patent drafting and prosecution having spent four years at another IP firm prior to joining EIP.

Rosie has a degree in biochemistry from the University of Edinburgh. She then attended Queens University Belfast where she completed a PhD in biochemistry at the Centre for Vision and Vascular Sciences. Her research centred on investigating the reasons underlying protein adduct accumulation in the diabetic retina.

Published articles

  • 15 August 2018
    Diabetologia, Müller glial dysfunction during diabetic retinopathy in rats is reduced by the acrolein-scavenging drug, 2-hydrazino-4,6-dimethylpyrimidine (link)
  • September 2016
    IOVS, Diabetes impairs the aldehyde detoxifying capacity of the retina (link)
  • 30 January 2013
    Future Medicinal Chemistry, The therapeutic potential for targeting lipid aldehydes and advanced lipoxidation end products in ocular disease (link)

Education and qualifications

UK Patent Attorney, 2018

European Patent Attorney, 2018

  • 2016
    EQE Pre-Examination
  • 2014
    PGCert Intellectual Property Law, Brunel University
  • 2010 — 2013
    PhD in Biochemistry, Queens University Belfast
  • 2006 — 2009
    BSc Biochemistry, University of Edinburgh

Career history

  • 2017 — present
    Associate, EIP
  • 2013 — 2017
    Technical Assistant (Life Sciences), Dehns